Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.

Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T.

Leukemia. 2012 Apr;26(4):716-9. doi: 10.1038/leu.2011.258. Epub 2011 Sep 16.

PMID:
21926959
2.

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A.

J Clin Oncol. 2011 Aug 10;29(23):3179-84. doi: 10.1200/JCO.2010.34.5298. Epub 2011 Jul 11.

PMID:
21747083
3.

Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.

Rupoli S, Goteri G, Picardi P, Micucci G, Canafoglia L, Scortechini AR, Federici I, Giantomassi F, Da Lio L, Zizzi A, Honorati E, Leoni P.

Diagn Pathol. 2015 Apr 16;10:29. doi: 10.1186/s13000-015-0269-1.

4.

Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.

Barbui T, Thiele J, Carobbio A, Passamonti F, Rumi E, Randi ML, Bertozzi I, Vannucchi AM, Gisslinger H, Gisslinger B, Finazzi G, Ruggeri M, Rodeghiero F, Rambaldi A, Gangat N, Tefferi A.

Blood. 2012 Jul 19;120(3):569-71. doi: 10.1182/blood-2012-01-407981. Epub 2012 Jun 13.

5.

Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.

Barbui T, Thiele J, Vannucchi AM, Tefferi A.

Leukemia. 2013 Oct;27(10):1953-8. doi: 10.1038/leu.2013.74. Epub 2013 Mar 7. Review.

PMID:
23467025
6.

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.

Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H.

Haematologica. 2012 Mar;97(3):360-5. doi: 10.3324/haematol.2011.047811. Epub 2011 Nov 4.

7.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.

PMID:
19616600
8.

Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients.

Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Müllauer L, Frantal S, Carobbio A, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Finazzi G, Gangat N, Tefferi A, Barbui T.

Am J Hematol. 2012 Jul;87(7):669-72. doi: 10.1002/ajh.23217. Epub 2012 May 10.

9.

Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage.

Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH.

Eur J Haematol. 2013 Mar;90(3):228-36. doi: 10.1111/ejh.12064.

PMID:
23281576
10.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
11.

Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia.

Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG, Kho BC, Lee HK, Sim JP, Chan CH, Chan JC, Yeung YM, Law M, Liang R.

Arch Intern Med. 2005 Dec 12-26;165(22):2651-8.

PMID:
16344424
12.

The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

Kc D, Falchi L, Verstovsek S.

Ann Hematol. 2017 Oct;96(10):1595-1604. doi: 10.1007/s00277-017-3099-2. Epub 2017 Aug 14. Review.

PMID:
28808761
13.

Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.

Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC.

Histopathology. 2010 May;56(6):758-67. doi: 10.1111/j.1365-2559.2010.03545.x.

PMID:
20546341
14.

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Ruggeri M, Rodeghiero F, Rambaldi A, Barbui T.

Blood. 2008 Oct 15;112(8):3135-7. doi: 10.1182/blood-2008-04-153783. Epub 2008 Jun 27.

15.

Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.

Tefferi A, Barbui T.

Leukemia. 2013 Aug;27(8):1617-20. doi: 10.1038/leu.2013.99. Epub 2013 Apr 5. Review.

16.

[The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].

Gong XB, Zhang XH, Lu XG, Tang QS, Gao X, Yang J.

Zhonghua Xue Ye Xue Za Zhi. 2012 Jan;33(1):25-30. Chinese.

PMID:
22575188
17.

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A.

Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26.

18.
19.

Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.

Jeryczynski G, Thiele J, Gisslinger B, Wölfler A, Schalling M, Gleiß A, Burgstaller S, Buxhofer-Ausch V, Sliwa T, Schlögl E, Geissler K, Krauth MT, Nader A, Vesely M, Simonitsch-Klupp I, Müllauer L, Beham-Schmid C, Gisslinger H.

Am J Hematol. 2017 Sep;92(9):885-891. doi: 10.1002/ajh.24788. Epub 2017 Jun 9.

PMID:
28543356
20.

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T.

Blood. 2011 Jun 2;117(22):5857-9. doi: 10.1182/blood-2011-02-339002. Epub 2011 Apr 13.

Supplemental Content

Support Center